Drug intelligence / Profile preview

ST-6280

Development stage: Preclinical
Lead developer: Beijing Scitech-Mq Pharmaceuticals
Modality: Small Molecules

Overview

ST-6280 is a blood-brain barrier (BBB)-penetrating small molecule inhibitor of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). Developed by Beijing Scitech-Mq Pharmaceuticals, it is specifically engineered to address central nervous system (CNS) complications of non-small cell lung cancer (NSCLC), such as brain metastases and leptomeningeal metastases. By inhibiting these tyrosine kinases, ST-6280 aims to disrupt signaling pathways that drive tumor growth and survival in the brain. The drug is designed for high CNS penetration to overcome the limitations of many existing targeted therapies. It is currently in the IND-enabling preclinical stage of development.

Targets

EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on ST-6280.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ST-6280.

Explore the full profile